Renaissance Technologies LLC Purchases 524,600 Shares of Humacyte, Inc. (NASDAQ:HUMA)

Renaissance Technologies LLC boosted its stake in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 693.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 600,300 shares of the company's stock after acquiring an additional 524,600 shares during the quarter. Renaissance Technologies LLC owned 0.50% of Humacyte worth $2,881,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HUMA. Endowment Wealth Management Inc. boosted its stake in Humacyte by 3.1% in the second quarter. Endowment Wealth Management Inc. now owns 100,518 shares of the company's stock worth $482,000 after purchasing an additional 3,000 shares in the last quarter. nVerses Capital LLC bought a new stake in shares of Humacyte during the second quarter valued at approximately $28,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Humacyte by 65.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 19,883 shares of the company's stock valued at $62,000 after purchasing an additional 7,897 shares in the last quarter. Principal Financial Group Inc. bought a new position in Humacyte in the 2nd quarter worth approximately $83,000. Finally, Hartline Investment Corp acquired a new position in Humacyte during the 1st quarter worth $70,000. 44.71% of the stock is owned by institutional investors.

Humacyte Stock Up 1.0 %

Shares of HUMA stock traded up $0.05 during trading on Tuesday, reaching $5.50. The company's stock had a trading volume of 2,476,886 shares, compared to its average volume of 2,217,930. Humacyte, Inc. has a one year low of $1.96 and a one year high of $9.97. The business has a fifty day moving average price of $6.54 and a 200-day moving average price of $5.71. The company has a market cap of $654.37 million, a price-to-earnings ratio of -5.44 and a beta of 1.47. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.61.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.04). Analysts anticipate that Humacyte, Inc. will post -1.09 earnings per share for the current year.

Insider Transactions at Humacyte

In other news, CEO Laura E. Niklason sold 157,704 shares of the company's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $5.42, for a total value of $854,755.68. Following the transaction, the chief executive officer now owns 3,519,558 shares of the company's stock, valued at $19,076,004.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Laura E. Niklason sold 157,704 shares of the business's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $5.42, for a total value of $854,755.68. Following the completion of the sale, the chief executive officer now owns 3,519,558 shares of the company's stock, valued at $19,076,004.36. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Laura E. Niklason sold 277,090 shares of the company's stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $6.47, for a total transaction of $1,792,772.30. Following the completion of the transaction, the chief executive officer now owns 4,029,374 shares in the company, valued at $26,070,049.78. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,084,153 shares of company stock worth $6,869,996. 23.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

HUMA has been the subject of a number of research reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $13.00 price objective on shares of Humacyte in a research report on Friday, September 20th. Benchmark reissued a "buy" rating and set a $15.00 price target on shares of Humacyte in a research note on Thursday, September 5th. EF Hutton Acquisition Co. I upgraded shares of Humacyte to a "strong-buy" rating in a report on Monday, September 9th. Finally, BTIG Research lifted their target price on shares of Humacyte from $8.00 to $11.00 and gave the stock a "buy" rating in a report on Monday, July 15th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $9.80.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.